• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Artificial dermis, artificial skin, methods for its preparation and its uses. The present invention relates to an artificial dermis comprising a first layer of coagulated blood plasma gel comprising platelets and dermal cells, and a second gel layer of coagulated blood plasma comprising platelets and dermal cells, and a network of located polymer between the first and second gel layers. The invention also relates to an artificial skin comprising said artificial dermis with at least one layer of epithelial cells. The invention discloses methods for the preparation of the artificial dermis and artificial skin, as well as its uses in the preparation of a medicament, in particular for the treatment of reepithelialization of a patient in need thereof. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2551143A1
    申请号:ES201430701
    申请日:2014-05-13
    公开日:2015-11-16
    发明作者:Santos MERINO ÁLVAREZ；Aritz RETOLAZA MUÑOA；Sabino Azcárate Leturia；José Luis JORCANO NOVAL；Almudena HOLGUÍN FERNÁNDEZ；Blanca DUARTE GONZÁLEZ；Álvaro MEANA INFIESTA；Eva GARCÍA PÉREZ；Sara GÓMEZ LLAMES
    申请人:Centro Comunitario De Sangre Y Tejidos De Asturias (ccst)；Ct Comunitario De Sangre Y Tejidos De Asturias Ccst；Centro de Investigaciones Energeticas Medioambientales y Tecnologicas CIEMAT；Fundacion Tekniker；
    IPC主号:
    专利说明:

    ARTIFICIAL DERMIS, ARTIFICIAL SKIN, METHODS FOR THEIR PREPARATION AND ITS USES
    FIELD OF THE INVENTION
    The present invention relates to an artificial dermis comprising gel layers made from coagulated blood plasma comprising platelets, and embedded dermal cells, and a polymer network between gel layers. The invention also relates to an artificial skin comprising said artificial dermis and additionally comprising epithelial cells that are sown on the surface of this artificial dermis. Both artificial dermis and artificial skin are especially useful for the treatment, for example, of major burns, chronic ulcers, in tests to control the sensitivity to different products, etc. Through the use of genetically altered cells, the dermis and artificial skin can also be used as a vehicle for genetic therapy.
    BACKGROUND OF THE INVENTION
    The skin is a tissue formed by two parts, the epithelium or external part and the dermis, or the internal part on which the epithelium is located. These two parts have clearly different characteristics. There is practically no extracellular tissue in the epidermis, while this component is clearly predominant over cells in the dermis.
    The skin is a tissue that can be reconstructed using tissue engineering techniques (Parenteau N, Sci Am,
    280: 83 84, 1999). In these techniques, in general, the cellular component is generated "ex vivo" by cell culture techniques. These techniques begin with a small number of cells taken from a small skin biopsy, which are then cultured or "expanded" to obtain a large number of cells in a short period of time. These expanded cells "ex vivo" can be used to develop large areas of artificial skin. The extracellular matrix cannot be produced by cell culture, but it is previously designed and prepared outside the body. The extracellular matrix must be able to provide structures that facilitate the adhesion of previously cultured dermal cells and that stimulate the normal growth of these cells. In this artificial matrix, the cells begin to make the normal proteins that constitute the natural dermal matrix, and at the same time, they slowly degrade the original structure, so that over time, this artificial matrix is replaced with an identical real extracellular matrix to a natural Previously cultured epithelial cells (keratinocytes in the case of the skin) can be seeded on this artificial matrix, in which with new cell culture techniques, these cells are capable of generating a structure that is very similar to the normal epithelium from which originate. In other words, one of the key factors in skin tissue engineering is the design of dermal matrices that mimic the natural conditions of the organism as much as possible, and in which the introduced cells are able to begin a complex process, whose end It is to develop a structure as similar as possible to natural skin.
    The other key factor in skin tissue engineering is the ability of the dermal matrix to facilitate the growth of cells that are planted on it. The development of dermal matrices that stimulate the growth of both dermal and epidermal cells would mean that it might be possible to grow large areas of artificial skin from a minor biopsy. This is especially important when artificial skin is to be used to treat significant burns, in which up to 90 -95% of the total body surface area has to be replaced as quickly as possible, using small areas of skin. healthy that remain in the patient. The lack of dermal matrices capable of generating these large areas of artificial skin from minor biopsies is one of the limitations of the dermal matrices described above (Sheridan R and Tompkins, Bums 25: 97103, 1999).
    There are several models of artificial dermis. For example, EP 1375647 B1 discloses a dermal matrix for use in the generation of an artificial dermis. In this model, the dermal matrix is prepared as follows: a blood plasma solution comprising platelets and additionally containing "ex-vivo" cultured dermal cells is prepared; said solution is then coagulated to form a gel layer on which keratinocytes are seeded and cultured until total or partial confluence. The gel layer thus obtained with the cultured keratinocytes can then be fixed to a solid support to allow transport without losing their integrity or degradation. As disclosed in EP 1375647 81, said solid support is fixed to the upper surface of the artificial dermis in which the keratinocytes are sown. In general, said support can be any solid support for example of polylactic polyglycolic acid; or it can be a silicon membrane in which case it can be fixed to the gel layer by an organic glue such as fibrin; or it can also be a gauze, soaked in petroleum jelly or not, which can be fixed using an inert inorganic glue for clinical use or another mechanical system. According to EP 1375647 81, the dermal matrix disclosed allows the preparation of an artificial dermis suitable for use in skin grafts, and has been used successfully in the treatment of bullous epidermolysis.
    However, the dermal matrix experiences drawbacks and its application for example in therapy is not entirely satisfactory. One of these disadvantages is that extremely careful handling is required to ensure that the matrix sheet remains intact and suitable for the implant.
    Other artificial skin substitutes include the use of polymeric structures such as frameworks for the cultivation of artificial skin. Dermagraft ™ dermal replacement for use in the treatment of diabetic foot ulcers is prepared by sowing fibroblasts on a mana of polygalactin. Additionally, keratinocyte culture on a polymer surface is also known, either alone (document W099 / 064563) or in conjunction with fibroblasts (document WOO1 / 066695).
    In view of the foregoing, there is still a need in the state of the art to provide an alternative artificial dermis and an alternative artificial skin that overcome at least some of the drawbacks associated with the dermis and artificial skins of the prior art, which show greater strength and firmness, are easier to handle, and allow an improved, effective treatment of patients requiring reepithelialization. Detailed description of the invention
    In a first aspect, the invention relates to an artificial dermis comprising a first layer of coagulated blood plasma gel comprising platelets and dermal cells, a second layer of coagulated blood plasma gel comprising platelets and dermal cells, and a network of polymer located between the first and second gel layers.
    The artificial dermis, hereinafter referred to as the artificial dermis of the invention, has a defined thickness of about 0.15 cm to about 5 cm, preferably about 0.3 cm to about 1.0 cm.
    The artificial dermis of the invention can be generated in a wide variety of sizes that vary, by
    For example, between about 1 cm and about 100 cm, more preferably from about 10 cm 2 to about 90 cm 2, even more preferably from about 30 cm 2 to about 80 cm. The artificial dermis can also have different forms.
    The artificial dermis of the invention preferably has one or more substantially linear edges, which allow for easy alignment of individual sections of artificial dermis together during implant procedures. The dermis has a degree of elasticity, and for this reason the edges do not need to be exactly linear to allow mutual alignment, as the person skilled in the art quickly observes.
    The polymer network of the artificial dermis consists of a polymeric sheet comprising pores. The pores may have different shapes and sizes depending on the method for their manufacture. The shapes of the pores can be very different, ranging from square to circular, including for example elliptical pores, without limitation. Pore sizes may also vary within a wide range, and generally have between 10 jJm and 1000 IJm in diameter in the case of circular pores, or have a side between 10 jJm and 1000 IJm in the case of Square pores
    Since the artificial dermis is intended for use in the treatment of a patient in need, the polymer is preferably biocompatible and biodegradable.
    The term "polymer" is intended to include any compound that is formed by monomer repeat units, and therefore includes polymers formed by a single monomer unit, and copolymers formed by at least two different monomers, for example, 2, 3, 4 or more
    According to a particular embodiment, said polymer can be selected from the group consisting of poly (methyl O methacrylate), polylactide, which includes poly (L-Iactide) (LPLA) and poly (dJ-lactide) (OLPLA ), polyglycolide (PGA), poly (lactic-co-glycolic acid) (PLGA), polycaprolactone, (such as poly (r-caprolactone) (PCLl), polydioxanone (POO), poly (glycolide-co-trimethylene-carbonate) , polyglyconate and mixtures thereof According to a preferred embodiment, the polymer is PLGA When PLGA is used, it is more preferred that at least 50% of the monomer units be lactic acid In an alternative embodiment, the ratio of units Lactic acid to glycolic monomer ranges from about 1: 1 to about 17: 3. Table 1 provides several examples of polymers, in general, and several examples of PLGA copolymers having suitable ratios of lactic acid units to glycolic acid. , for example 85115; 75125; 65/35; Y 5 0150. These relationships can be applied similarly to other copolymers.
    The artificial dermis of the invention may comprise one or more additional gel layers and one or more polymer nets in addition to the artificial dermis as described above with a first gel layer, a polymer network, and a second layer of gel. In these embodiments of the artificial dermis of the invention, the alternating arrangement of the polymer net / gel layer gel layer is maintained. In this sense, examples of possible artificial dermis of the invention have the following repetition structures:
    (i) polymer gelfred layer / gel layer / polymer net, or
    (ii) polymer gelfred layer / gel layer / polymer net / gel layer, or
    (iii) polymer gelfred layer / gel layer / polymer net / gel layer / polymer net,
    and so on.
    Accordingly, the artificial dermis of the invention includes 2, 3, 4, 5, or several gel layers. Consequently, the artificial dermis of the invention induces 2, 3, 4, or even more polymer networks.
    The artificial dermis of the invention is more robust and firm than the dermis disclosed in EP 1375647 B1, and this is not only due to mechanical support and consistency provided by the polymer network, but also due to the fact that the cells communicate through the pores of the network.
    The gel layers of the artificial dermis may be the same or different with respect to their composition, for example with respect to the type and origin of their dermal cells. When the artificial dermis comprises at least two polymeric networks, the polymeric networks may also be of the same or different type, with respect to their composition and their characteristics.
    In this sense, various polymer network thicknesses can be used, and the thicknesses can vary between different polymer networks within the same artificial dermis. Examples of suitable thicknesses are those ranging from about 10 micrometers to about 100 micrometers, preferably from about 10 micrometers to about 40 micrometers, and even more preferably from about 25 micrometers to about 35 micrometers.
    The gel layers of the artificial dermis of the invention comprise dermal cells such as mesenchymal stem cells (MSC), endothelial cells, or fibroblasts. According to a preferred embodiment, the dermal cells are fibroblasts. According to the invention, the dermal cells present in the first and second gel layers, and in other additional gel layers, when appropriate, can be of the same or different type and origin.
    The blood plasma used to prepare the gel layer comprising platelets and dermal cells can have their origin in any animal source. According to a particular embodiment, blood plasma and dermal cells are of human origin. Both blood plasma and dermal cells may have their origin in a suitable donor subject (that is, they may be allogeneic with respect to the patient to be treated with the artificial dermis or with the artificial skin of the invention) or they may have autologous origin ( that is, they may have their origin in the same patient to be treated).
    Suitable sources of dermal cells include, but are not limited to, cell lines and biopsies, for example skin. The dermal cells are most preferably isolated from the tissue of the donor or patient subject and then cultured or expanded "ex-vivo" before use in the preparation of the gel layers of the artificial dermis. methods for cell culture or expansion.
    For example, in one embodiment of the invention, fibroblasts can be isolated from the dermal sample of a donor or a patient in need of treatment. The dermal sample is treated with collagenase which therefore releases the fibroblasts, which are then isolated (for example, by centrifugation) and then cultured "ex-vivo".
    MSCs can be obtained from any suitable source of connective tissue from any suitable animal, but preferably they will be of human origin. It is preferred that the MSCs are obtained from non-pathological mammalian sources, preferably post-natal (for example, rodents: primates). In a preferred embodiment, the MSCs are obtained from a source of connective tissue, such as, but not limited to, the stromal fraction of adipose tissue, hyaline cartilage, bone marrow or skin. Preferably, MSCs are obtained from post-natal, non-pathological, human stromal adipose tissue.
    Suitable sources of fibroblast cells include, but are not limited to, cell lines and biopsies, for example fibroblasts cultured from foreskin obtained in phimosis operations and {or dermal fibroblasts from healthy adults, obtained, for example, from of a skin biopsy; Anthologous fibroblasts, for example, can be obtained from a skin biopsy removed from the same subject to be treated with the artificial dermis or artificial skin of the invention.
    As an example, different lines of human fibroblasts will be obtained from human foreskins obtained after programmed phimosis surgery or from a skin biopsy. The sample is collected in a transport medium (Dulbecco-modified eagle medium (DMEM), 10% fetal bovine serum albumin, 100 u {ml of penicillin, 100 ~ g {ml of streptomycin). In the laboratory, the sample is washed, preferably three times in sterile phosphate buffered saline (PBS), and carefully cut into pieces. 0.05% trypsin and 0.02% ethylenediaminetetraacetic acid solution (EDTA) can be introduced into 30 ml while stirring at 37 ° C. Every 30 minutes, trypsin is collected and changed to freshly prepared trypsin. Then, trypsin is neutralized by the addition of complete culture medium (eg, DMEM, 10% fetal bovine serum). The operation is repeated until no more cells are obtained. The cells obtained are placed in a culture plate at a density of 100,000 cells per cm2 of culture surface. The medium is changed every 72 hours until the cells are confluent. After confluence, these cells can be trypsinized and secondary cultures can be prepared in a proportion of two culture plates for each culture plate in the previous phase. When the cells show a single layer of fibroblast-like cells, some of them can be frozen, using the usual technique, and stored in cryovials in liquid nitrogen. The ideal passes for the use of these fibroblasts are between 40 and 12 °.
    When human fibroblasts are used in the artificial dermis of the same patient to be treated, it is possible to proceed in the same way. For example, a biopsy of the patient's skin can be processed as described above. Once the cells are obtained, part of them can be grown, for example, in
    i
    DMEM 10% fetal bovine serum at a density of approximately 100,000 cells per cm. The corresponding subcultures can be propagated until a sufficient number of human fibroblasts are obtained to prepare the artificial dermis that the patient needs.
    The cultured human fibroblasts can then be trypsinized, counted and resuspended in culture medium, preferably for immediate use in the preparation of the artificial dermis of the invention.
    Preferably, the dermal cells are provided in each of the gel layers as a layer of confluent or partially confluent cells. The degree of confluence can vary between a confluence of 50% and 100%, for example, a confluence of at least 60%, or at least 70%, or at least 80%,
    or at least 90% or at least 100%. The initial concentration of dermal cells within the gel can vary considerably. In general, a concentration of not less than 500 dermal cells / cm 2 of gel surface is recommended, although it may be greater, but preferably less than 4,000 cells / cm 2.
    Blood plasma comprising platelets for use in the preparation of the gel layers of the artificial dermis of the present invention can be prepared by any means known in the art, as will be observed by the reader skilled in the art, including preparation from whole or whole blood Blood can be extracted with conventional means, such as puncture in the vein. It is preferred that the extraction of whole blood be carried out in the presence of anticoagulant agents suitable for use in clinical situations, preferably agents acting by chelation of the concentration of ionized calcium in the whole blood (e.g., sodium citrate, EDTA, or sodium heparin). Blood may be extracted and / or stored in containers known in the art for such purposes, such as hemotherapy bags or, for small quantities, small Vacutainer type containers. Next, blood plasma comprising platelets can be isolated from whole blood extracted with means known in the art such as low speed centrifugation (about 1500 rpm, preferably for 5 minutes; about 160 g) to obtain a plasma blood that is very rich in platelets, or at high speed (between 2900-3000 rpm, preferably for 10 minutes; about 400 g) to obtain a product with a lower concentration of said platelet cells. In a particular embodiment of the invention, blood plasma can be enriched in growth factors, such as those of platelet origin. The person skilled in the art is capable of enriching platelet factors during plasma preparation by selecting appropriate centrifugation techniques, using his usual general knowledge. As an alternative, blood plasma can also be extracted from whole blood by plasmapheresis.
    Once the blood plasma has been isolated, it can be used directly to form a gel layer according to the invention or it can be frozen, for example, at -20 OC for later use. Before storage, plasma can also be treated to ensure that all microorganisms are removed, for example, by treatment with methylene blue. This is particularly important if the plasma is to be used in the preparation of a dermis or artificial skin for the treatment of a non-donor subject (ie allogeneic).
    The blood plasma used in the preparation of artificial dermis of the present invention comprises fibrinogen. This is preferably at a minimum level of about 1.67 mg / ml, preferably at least about 2 mg / ml. However, the level can also be as low as 0.4 mgfml, or as high as 4 mgfml. As an example, between about 2 ml and about 30 ml of blood plasma can be used in the preparation of a gel layer having a surface area of about 70 to about 90 square centimeters.
    A detailed description of methods for the preparation of dermal layers from blood plasma and dermal cells is contained in EP 1375647 81 from paragraph [0007] to [0044], the contents of which are incorporated herein by reference.
    In a further aspect, the invention relates to a method for the preparation of the artificial dermis of the invention, comprising the following steps:
    Provide a first and optionally also a second reaction solution comprising blood plasma with platelets and dermal cells,
    (ii) Coagulate at least a portion of the first reaction solution to provide a first layer of coagulated blood plasma gel comprising platelets and dermal cells,
    (iii) Apply a polymer net on said first gel layer,
    (iv) Coagulate an additional part of the first reaction solution or at least a part of the second reaction solution comprising blood plasma with platelets and dermal cells, on the surface of the aforementioned polymer network to provide a second gel layer of coagulated blood plasma comprising platelets and dermal cells.
    In the first stage of the method, a first reaction solution is prepared comprising blood plasma with platelets and dermal cells. Optionally, a second reaction solution is prepared if an artificial dermis with different gel layers is desired. A reaction solution can be prepared by combination or by blood plasma mixture comprising platelets, obtained as previously disclosed, with dermal cells obtained and cultured as described above, so that the dermal cells are dispersed or Suspend inside the plasma. Similarly, different dermal cells can be used with respect to their type and origin to prepare a reaction solution.
    The reaction solution can be diluted with appropriate agents, for example, but not limited to saline.
    In the second stage of the method, a first gel layer is formed from a part of the first reaction solution. This part of the reaction solution is preferably placed inside a container or mold that is suitable for the formation of an essentially flat gel layer, and then coagulated by treatment under suitable conditions such that the solution is converted into a gel. Methods for preparing a gel from a reaction solution are well known in the art, and include treatment with coagulation agents, such as, but not limited to calcium salts (for example, a 1% calcium chloride, dissolved for example in 0.9% sodium chloride) and exogenous thrombin.
    The gel is formed from the fibrinogen present in the plasma, by the action of human thrombin or exogenous bovine and calcium ions. In an alternative embodiment, the coagulation process can be achieved by the addition of non-protein agents.
    Blood-derived plasma, unlike fibrinogen concentrates well known in the state of the art, provides all components for the coagulation cascade, including thrombin that is present in the form of its (inactive) precursor, prothrombin . The gelation, and therefore the production of the gel layer gives the artificial dermis, can be performed by stimulating the intrinsic coagulation pathway by adding calcium in the presence of phospholipids of platelet origin. It is particularly preferred that the gel is formed, at least in part, by the conversion of fibrinogen to fibrin which then provides the component of the main structure of the gel. Other structural components of the gel may include, for example, plasma fibronectin.
    In addition, other proteins that are present in the blood plasma, for example, albumin, globulins, growth factors, plasminogen, etc., are involved in the formation and stability of the gel and in the growth of cells grown in the gel.
    Optionally, gel formation by means of coagulation agents can be aided by the addition of anti-fibrinolyl agents to the reaction solution, such as, but not limited to aprotonin, tranexamic acid (TXA), and E-aminocaproic acid. (EACA). The use of said agents is preferred when the reaction solution comprises 2 mgfml or less of fibrinogen.
    In the third stage, a polymer network is applied on said first gel layer by manual means.
    The polymer network has been obtained previously by conventional methods of the technique. In a particular embodiment, the net is prepared by hot stamping. In this particular case, a manufactured silicon seal is used as referenced in (1) ['The influence of stamp deformation on residual layer homogeneity in thermal nanoimprint lithography ". S. Merino, A. Retolaza, A. Juarros, H. Schift Microelectronic Engineering 85 (2008) 1892], which presents the inverse of the formation of 3D patterns to be stamped on the polymer sheet, the seal and the polymer sheet are heated to a temperature greater than the transition temperature v Treate the polymer and apply a force to the battery at this temperature.The polymer flows, and occupies the three-dimensional mold motifs, then the battery is cooled to temperature and unmold (2) ['The use of automatic demoulding in Nanoimprint Lithography processes ". S. Merino, H. $ chifl, A. Retolaza, T. Haatainen. Microelectronic Engineering 84 (2007) 958]. A polymer structure with a 3D patterned pattern is obtained. The sheet with the 3D pattern is then inserted into a vacuum chamber. Next, oxygen plasma is applied to the polymer sheet in order to achieve holes that cross the polymer sheet while the pattern is maintained throughout the surface.
    The artificial dermis and artificial skin of the present invention can be removed from the mold and directly applied a patient.
    It is particularly preferred that the polymer network be applied before the end of the previous gelation step, but after the addition of any gelling or coagulation agent (ie, the polymer network is thus applied to a semi-solidified surface before the end of the gelation process). In one embodiment of the method, in which an exogenous agent or agents (for example thrombin and calcium) is added to the reaction solution to induce the formation of a gel, the polymer network is applied between about 5 minutes and 30 minutes later. of the addition of said agent or agents (for example, at 10.15, 20, or 25 minutes).
    In the fourth stage, a second gel layer is formed from an additional part of the same reaction solution used in the first gel layer or from a different reaction solution. This part of a reaction solution is applied to the surface of the polymer network and then coagulated by treatment under suitable conditions so that the solution is converted into a second gel layer. Coagulation can be performed by any of the means that have been previously disclosed.
    According to a particular embodiment of the method, step (iv) and optionally also step (iii) can be repeated in this order to provide an artificial dermis with the structures that have been previously disclosed. Therefore, steps (iii) and (iv) can be repeated 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times to provide an artificial dermis comprising a plurality of gel layers and polymer nets.
    In addition to step (iv), the method for preparing the artificial dermis of the invention may comprise storage of the artificial dermis under appropriate conditions until confluence or preconfluence of the dermal cells within said artificial dermis is achieved. In one embodiment of the method, this may take between about 8 and about 12 days. Consequently, the present invention provides an artificial dermis of the invention having dermal cells having a confluence of at least 60%, 70%, 80%, 90% or even 100%.
    The artificial dermis of the present invention can be stored in an appropriate culture medium at a maximum of 37 ° C before application to a patient.
    In a further aspect, the invention relates to an artificial skin, also referred to hereinafter as the skin of the invention. The skin of the invention comprises the artificial dermis of the present invention and at least one epithelial cell layer.
    Said at least one layer of epithelial cells can in principle be placed in any position between any gel layer and a contiguous polymer network of the artificial dermis. According to a preferred embodiment, said at least one layer of epithelial cells is placed on the elderior surface of the artificial dermis. According to a particular embodiment, said elderna surface of the dermis is of a gel layer. According to another particular embodiment, said outer surface is of a polymer network.
    The epithelial cells of the layer may have their origin in any suitable animal source but most preferably they are of human origin. Epithelial cells may have their origin in a suitable donor subject (that is, they may be allogeneic with respect to the patient treated with the artificial dermis or artificial skin of the invention) may have or govern autologous (i.e., may have their origin in the same patient to be treated).
    The epithelial cells are most preferably isolated from donor or patient subject tissue and cultured are not expanded ~ ex-vivo "before use in the preparation of the artificial skin or epidermis as disclosed below. Sources Suitable epithelial cells include, but are not limited to cell lines and biopsies.
    Methods for culturing epithelial cells are well known in the art and any suitable method can be used. This may include, for example, cell culture in the presence of feeder cells (such as, but not limited to, irradiated 3T3-Swiss cells), or the use of specialized cell culture media such as, but not limited to, low media in calcium.
    In another aspect, the invention relates to a method for preparing the artificial skin of the invention. This method comprises the following stages:
    (;) prepare an artificial dermis according to the present invention,
    (ii) sow epithelial cells on at least the surface of a layer of gel or polymer network; Y
    (iii) culturing the cells until a layer of epithelial cells is produced.
    Preferably, the epithelial cells are seeded at a density of between about 1,500 and about 15,000 cells per square centimeter of surface area of the artificial dermis (e.g., 2,500; 5,000; 7,500; 10,000; 12,500 cells per cm2).
    The epithelial cells placed on the surface of the artificial dermis will adhere and proliferate under appropriate culture conditions, as well as the dermal cells within the artificial dermis gel, during step (jii), the epithelial cells forming a layer.
    Accordingly, in a particular embodiment, step (iii) is performed by storing the artificial skin obtained in step (ii), under conditions suitable for the culture of epithelial cells, preferably in a culture medium or other suitable liquid. The person skilled in the art will be aware of the appropriate conditions for the culture of these cells and may include the use of culture media and a controlled environment appropriate to implement step (iii).
    The storage is carried out under appropriate conditions until a confluence or preconfluence of the dermal cells and epithelial cells is achieved on the surface of yfo within said artificial dermis. In one embodiment of the method, this may require between about 8 and about 12 days. Accordingly, the present invention provides an artificial skin of the invention that has epithelial cells and dermal cells on the yfo surface within the artificial dermis that has a confluence of at least 60%, 70%, 80%, 90 % or even 100%.
    The artificial dermis and artificial skin of the present invention can be stored at a maximum of 37 ° C in an appropriate culture medium before application to a patient in need thereof.
    The artificial dermis and the artificial skin of the present invention can be used in therapy. In this regard, one aspect of the invention relates to the use of the artificial dermis or artificial skin of the invention for the preparation of a medicament. In the present context, a medicament refers to a preparation comprising the artificial skin or artificial dermis of the invention, which is suitable for application as a graft in a patient in need of treatment with it.
    According to a particular embodiment, the use of the artificial dermis or artificial skin is for the preparation of a medicament for the reepithelialization treatment of a patient in need.
    Furthermore, in a particular embodiment, said reepithelialization is of a mucosal, dermal or epidermal tissue of a patient.
    Therefore, the artificial dermis and artificial skin of the invention are for use in the treatment of a defect or disorder of the dermal, epidermal or mucosal tissues. The artificial dermis and artificial skin of the present invention can be used as a replacement or substitute for mucosal, dermal or epidermal tissues of a patient, including, but not limited to, those listed in Table 2. The Artificial skin used as such a replacement or substitute preferably comprises a simple non-stratified epithelium but may alternatively comprise an appropriate epithelium as described in Table 2.
    The invention includes the artificial dermis or artificial skin of the invention for use as a surgical graft, for example in the replacement of mucosal, dermal or epidermal tissues that include, but are not limited to, those disclosed in Table 2. In some embodiments, the invention includes a method for use of the artificial dermis or artificial skin in a surgical procedure, so that the surgical procedure is applied directly to the location of the subject graft.
    The artificial dermis and artificial skin of the present invention are also for use in the repair, treatment, and prevention of skin conditions, disorders or diseases, such as burn symptoms, which include, but are not limited to first-degree burns. degree, second degree burns and third degree burns; wound symptoms, which include but are not limited to epidermal wounds, skin wounds, chronic wounds, acute wounds, external wounds, internal wounds and congenital wounds (eg bullous epidermolysis); and ulcer symptoms that include, but are not limited to, pressure ulcers and diabetic ulcers.
    The process of the present invention is illustrated below by reference to examples that are intended to be illustrative only and are not construed as limiting the present invention in any way.
    EXAMPLESTable 1: Polymers suitable for use in the artificial dermis of the present invention.
    Polymer Melting point, Tm ("elGlass transition temperature, Ta ("elTensile strength I (GPalDegradation time I fm eses) '
    Pol i POL Pol i L-Iactida) (LPLA) 225-230 173-17835-40 60-6570 2.76-12> 24
    Poly- (dl (DLPLA) 'lactide) Amorphous55-651.912-16
    Pol i (r-caprolaclone) (PCL) 58-63(-65) - (- 60)0.4> 24
    Polydioxanone POO) NID-10) -01.56-12
    Pol i (glycolide-cotrimethylene-ca rbonate) or pol iQliconato (PGA-TMCl NIDNID2.46-12
    85/15 PLGA Amorphous50-55twenty5-6
    75/2 5 PLGA Amorphous50-55twenty4-5
    65/35 PLGA 50/50 PLGA Amorphous Amorphous45-50 45-502.0 2.03-4 1-2
    a: Degradation time in vivo. This time depends on the size of the final substrate.
    b: PLGA refers to the poly (lacrylic-co-glycolic acid) copolymer and ab / cd shows the mass composition of each polymer in the polylactic / polyglycolic copolymer.
    c: Both polymers are normally referred to as poly-laclide polymers. Table 2: Uses of artificial dermis or artificial skin.
    ~
    ,
    I feminine
    I I
    SAW,",'
    N., to I
    ~
    , i don't
    i i
    r simple, not ciliated r simple, not ciliated
    e "mp ~ r, ;; I, do
    ,, 'mpl., ,, 'mpl. i don't
    i i
    í i i i i don't
    i i i ciliated
    I ~
    ~, "00
    i i
    I I "and I no
    权利要求:
    Claims (13)
    [1]
     REVIVICATIONS
    one. An artificial dermis comprising a first layer of coagulated blood plasma gel comprising platelets and dermal cells, and a second layer of coagulated blood plasma gel comprising platelets and dermal cells, and a polymer network located between the first and second gel layers
    [2]
    2. An artificial dermis according to claim 1 wherein the polymer network comprises pores having an average diameter between 10 IJm and 1000 IJm.
    [3]
    3. An artificial dermis according to claim 2, wherein the polymer network is constituted by interwoven polymer strands each strand having an average diameter of 10 IJm to 1000 IJm.
    [4]
    Four. An artificial dermis according to any one of claims 1 to 3, wherein said polymer is biocompatible and biodegradable.
    [5]
    5. An artificial dermis according to claim 4 wherein said polymer is selected from the group consisting of poly (methyl methacrylate), polylactide, polyglycolide, poly (lactic-co-glycolic acid), polycaprolactone, polydioxanone, poly (glycolide -co-trimethylene carbonate), polyglyconate and mixtures thereof.
    [6]
    6. An artificial dermis according to claim S, wherein said polymer is poly {lactic-coglycolic acid).
    [7]
    7. An artificial dermis according to any one of the preceding claims, wherein the dermal cells of the first and second gel layers can be of the same or different types.
    B. A method for the preparation of an artificial dermis according to any one of the preceding claims, comprising the steps of:
    (i) Provide a first reaction solution and optionally a second reaction solution comprising both blood plasma with platelets and dermal cells,
    (ii) Coagulate at least a portion of the first reaction solution to provide a first layer of coagulated blood plasma gel comprising platelets and dermal cells,
    (iii) Apply a polymer net on said first gel layer,
    (iv) Coagulate an additional part of the first reaction solution or at least a part of a second reaction solution comprising blood plasma with platelets and dermal cells, on the surface of said polymer network to provide a second gel layer of coagulated blood plasma comprising platelets and dermal cells.
    [9]
    9. An artificial skin comprising an artificial dermis according to any one of claims 1 to 7, and at least one layer of epithelial cells.
    [10]
    10. An artificial skin according to the preceding claim, wherein the at least one layer of epithelial cells is placed on the outer surface of the artificial dermis.
    [11]
    eleven. A method for preparing an artificial skin according to claims 9-10, comprising:
    (iv) preparing an artificial dermis according to claims 1 to 7,
    (v) sow epithelial cells on at least one layer of gel or polymer network: and
    (saw) Cultivate the cells until a layer of epithelial cells is produced.
    [12]
    12. Use of an artificial dermis or artificial skin according to the preceding claims 1 to 7 or 9-10, for the preparation of a medicament.
    [13]
    13. Use of the artificial dermis or artificial skin according to claim 12, for the preparation of a medicament for the reepithelialization treatment of a patient in need.
    [14]
    14. Use of the artificial dermis or artificial skin according to claim 13, wherein the reepithelialization is of a mucous, dermal or epidermal tissue.
    类似技术:
    公开号 | 公开日 | 专利标题
    Ye et al.2018|Polyester elastomers for soft tissue engineering
    Do Kim et al.2004|Effect of PEG–PLLA diblock copolymer on macroporous PLLA scaffolds by thermally induced phase separation
    US9168125B2|2015-10-27|Artificial dermis and method of preparation
    Yao et al.2009|In vitro angiogenesis of 3D tissue engineered adipose tissue
    ES2256420T3|2006-07-16|MEDIA OF POROUS TISSULAR ANDAMIAJE FOR THE REPAIR AND REGENERATION OF DERMAL FABRIC.
    KR100905900B1|2009-07-02|Double Layered Scaffold for Treatment of Articular Cartilage
    KR100839875B1|2008-06-19|Scaffold for articular cartilage regeneration
    Lin et al.2015|In vitro and in vivo evaluation of the developed PLGA/HAp/Zein scaffolds for bone-cartilage interface regeneration
    Cui et al.2009|Rapid Prototyping a Double-layer Polyurethane—collagen Conduit and its Schwann Cell Compatibility
    JPH10234844A|1998-09-08|Base material for regenerating cartilaginous tissue and regenerating method of cartilaginous tissue using the same
    BR112017001550B1|2020-12-01|production method of a tissue graft and dermoepidermal skin graft
    KR100737167B1|2007-07-10|Method for preparing of a porous osteochondral composite scaffold
    Shukla et al.2015|Acellular dermis as a dermal matrix of tissue engineered skin substitute for burns treatment
    KR100979628B1|2010-09-01|Porous beads having uniform pore structure for tissue engineering and its manufacturing method
    ES2551143B1|2016-07-01|Artificial dermis, artificial skin, methods for its preparation and its uses
    US20200324021A1|2020-10-15|3D Printed Scaffold Structures and Methods of Fabrication
    ES2659004T3|2018-03-13|Polymeric scaffolding for cardiac regeneration and protection against reperfusion injury
    US9629939B2|2017-04-25|Collagenous foam materials
    ES2304321B1|2009-09-11|PROCEDURE FOR OBTAINING THREE-DIMENSIONAL STRUCTURES FOR TISSULAR ENGINEERING.
    Dudziński et al.2010|Three dimensional polyethersulphone scaffold for chondrocytes cultivation—the future supportive material for articular cartilage regeneration
    Thanarak et al.2018|Enhanced collagen production from human dermal fibroblasts on poly |-methacrylate scaffolds
    Suh2008|Collagen fabrication for the cell-based implants in regenerative medicine
    VERONESI et al.2012|Development and clinical application of keratinocytes cultured on a hyaluronic ester membrane in burn patients
    KR20130006144A|2013-01-16|High exclamation macromolecules support and manufacturing method thereof, structure of macromolecules support-chondrocyte complex based on the same, and chondrocyte restructuring method using the same
    同族专利:
    公开号 | 公开日
    ES2551143B1|2016-07-01|
    WO2015173206A1|2015-11-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP0416702A1|1989-09-06|1991-03-13|H.C. Implants B.V.|Artificial skin|
    WO2002072800A1|2001-03-01|2002-09-19|Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas |Artificial dermis and production method therefor|
    ES2184623A1|2001-06-29|2003-04-01|Ct Investig Energeticas Ciemat|Artificial autologous skin secreting leptin and method for obtaining the same|
    WO2003041568A2|2001-11-15|2003-05-22|University Of Medicine & Dentistry Of New Jersey|A three-dimensional matrix for producing living tissue equivalents|KR101926331B1|2016-04-12|2018-12-07|안트로젠|Composition for alleviating or improving epidermolysis bullosa comprising Mesenchymal Stem cells-Hydrogel-Biodegradable scaffold or Mesenchymal Stem cells-Hydrogel-Nondegradable scaffold|
    法律状态:
    2016-07-01| FG2A| Definitive protection|Ref document number: 2551143 Country of ref document: ES Kind code of ref document: B1 Effective date: 20160701 |
    2021-09-15| FD2A| Announcement of lapse in spain|Effective date: 20210915 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201430701A|ES2551143B1|2014-05-13|2014-05-13|Artificial dermis, artificial skin, methods for its preparation and its uses|ES201430701A| ES2551143B1|2014-05-13|2014-05-13|Artificial dermis, artificial skin, methods for its preparation and its uses|
    PCT/EP2015/060395| WO2015173206A1|2014-05-13|2015-05-11|Artificial dermis, artificial skin, methods for their preparation and their uses|
    [返回顶部]